StockUS listing USEQNASDAQHealthcareEarnings Deterioration

Equillium Inc(EQ) Stock Analysis | Healthcare

USD --+0.00%
Reward30Low
Risk72High
75%Data
Revenue down 52% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 87.26M
Reward Ratingⓘ30 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on EQ to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Equillium Inc?

, a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.

AI Brief Pro

The brief on Equillium Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Equillium Inc?

, a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 87.26M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (30)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.039
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
8406,392 shares
$1.2M
0
6-9months
2301,531 shares
$663k
0
9-12months
8336,272 shares
$542k
0